
Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Office of Public Records 232 Hart Building Washington, DC 20510



LOBBYING REPOR

LOBBYING REPOR	RT 02 AUG 21 AM 11:00
Lobbying Disclosure Act of 1995 (Section 5) - All Filers	
 Registrant Name Covington & Burling Address	, D.C.
3. Principal Place of Business (if different from line 2)	
City:	State/Zip (or Country)
4. Contact Name Telephone Er	nail (optional) 5. Senate ID #
7. Client Name Self Pharmaceutical Research & Manufacturers of	6. House ID #
TYPE OF REPORT 8. Year 2002 Midyear (January	1-June 30) OR Year End (July1-December 3
9. Check if this filing amends a previously filed version	of this report
10. Check if this is a Termination Report ☐ ⇒ Termi	nation Date 11. No Lobbying Acti
INCOME OR EXPENSES - Complete Either Li	ne 12 OR Line 13
12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for t reporting period were:
Less than \$10,000	Less than \$10,000
\$10,000 or more \boxtimes \Rightarrow \$\frac{280,000}{\text{Income (nearest \$20,000)}}	\$10,000 or more \square \Rightarrow \$_Expenses (nearest \$20,
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client.)	14. REPORTING METHOD. Check box to expense accounting method. See instruction description of options.
	Method A. Reporting amounts using LDA definitions only
	Method B. Reporting amounts under secti 6033(b)(8) of the Internal Rev
	Code Method C. Reporting amounts under 162(Internal Revenue Code
DAR-A 11	/ <u> </u>

Registrant Name

Covington & Burling

Client Name

Pharmaceutical Research & Manufacturers of America, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate pag code, provide information as requested. Attach additional page(s) as needed.
15. General issue area code HCR (one per page)
16. Specific lobbying issues
Drug Legislation
17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives Senate
18. Name of each individual who acted as a lobbyist in this issue area
Name Covered Official Position (if applicable)
Peter Barton Hutt Bruce N. Kuhlik Partner Partner
19. Interest of each foreign entity in the specific issues listed on line 16 above
Signature

Covington & Burling

Client Name

Pharmaceutical Research & Manufacturers of America, Inc.

20. Client new address	_			
21. Client new principal plac	ce of business (if di	fferent from line 20)		
City 22. New general description	C 1' 4 1	State/Zi	p (or Country)	
22. New general description	of chent's business	or activities		
LOBBYIST UPDATE 23. Name of each previously		who is no longer expec	eted to act as a lobbyist for	the clie
23. Paine of each proviously	reported marridae.	who is no longer emper	100 to 101 us a 1000 j 150 101	
ISSUE UPDATE				
24. General lobbying issues p	reviously reported	that no longer pertain		
AFFILIATED ORGA 25. Add the following affilia				
Name		Address	Principal Place o	
26. Name of each previously	reported organizati	on that is no longer affi	liated with the registrant or	client
FOREIGN ENTITIES				
27. Add the following foreig Name	n entities Address	Principal place of business	Amount of contribution	Owr
		(city and state or country)	for lobbying activities	perc clier
28. Name of each previously registrant, client or affiliation		ntity that no longer own	s, <u>or</u> controls, <u>or</u> is affiliate	ed with
0	<i>(</i>)			
a. It	Bester	ditt		
Signature	Peter Barton Hu		ate <u>August 12, 2002</u>	

Peter Barton Hutt